M1-c6v1
AXP000129.1 · Oncolytic virus
- Platform
- oncolytic alphavirus M1 (engineered variant)
- Originator
- Sun Yat-sen University
- Sponsor
- Guangzhou Virotech Pharmaceutical
Names
| Name | Type | Source |
|---|---|---|
| M1-c6v1 | preferred name, code | curator, ctgov |
Virus
- Role
- Oncolytic
- Family
- Togaviridae
- Virus
- Getah virus (NCBI Taxonomy 59300)
- Strain
- M1-c6v1
- Replication
- replicating
- Modifications
- engineered M1 alphavirus variant; details not disclosed
- Route
- intravenous
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06046742 | A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 | 2024-07-10 | 2028-06-30 | 12 | Solid Tumor |
| NCT04665362 | IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC | Unknown | Phase 1 | 2021-01-25 | 2022-06-01 | 10 | Advanced/Metastatic Hepatocellular Carcinoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40788183 | Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | name in title: M1-c6v1 |
Notes
Engineered M1 variant given intravenously (NCT06046742); entered separately from VRT106 because the two were taken into humans as different agents by the same sponsor. Whether they are genuinely different constructs needs checking with the sponsor.
How to cite
M1-c6v1 (AXP000129.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000129.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.